Tuesday's Health Winners & Losers

05/08/07 - 04:44 PM EDT

Elizabeth Trotta

Updated from 2:02 p.m. EDT

Some companies' weak earnings were balanced by others' strong quarterly results, leaving health stocks largely flat on Tuesday.

Medical device manufacturer DJO's(DJO Quote - Cramer on DJO - Stock Picks) shares slid 13.1% after the company reported disappointing first-quarter earnings. The company reported first-quarter revenue of $114.9 million, a 39% increase from the $82.6 million in revenue it reported in the same quarter last year. However, quarterly net income was $4 million, or 17 cents a share, compared to $6 million, or 26 cents a share, in the first quarter of 2006. The Thomson Financial consensus target was 31 cents a share on revenue of $114 million for the period. Shares fell $5.24 to $34.75 on Monday.

Biotechnology company Momenta Pharmaceuticals(MNTA Quote - Cramer on MNTA - Stock Picks) saw its shares sink 7.2%, following a disappointing earnings report. The company had a net loss of $17 million, or 48 cents a share, compared with a loss of $11.3 million, or 37 cents a share, in the year-over-year quarter. The Thomson Financial consensus targeted a loss of $15.7 million, or 43 cents a share. Shares dropped 99 cents to $12.77.

However, not everyone suffered poor earnings.

Biopharmaceutical company Allos Therapeutics (ALTH Quote - Cramer on ALTH - Stock Picks) reported that it met analysts' expectations with a net first-quarter loss of $8.4 million, or 14 cents a share, compared to a loss of $7.1 million, or 13 cents a share, in the year-ago quarter. Shares were up 18 cents, or 3.1%, to $6.03.

« Previous Page
1 2
Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Free Newsletters from TheStreet

Cramer's Daily Booyah!
Highlights of Jim Cramer's videos
on TheStreet.com TV & his
"Mad Money" TV show.
Before the Bell
All the information you
need to position yourself
for the day ahead.
Submit
We respect your privacy.

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!